GLP-1 Drug Exenatide Boosts Frataxin Protein in Friedreich Ataxia Across Three Evidence Levels
Exenatide increased frataxin protein in mouse brains, patient-derived neurons, and modestly in a pilot human trial, showing promise for this untreatable neurodegenerative disease.
Quick Facts
What This Study Found
The study tested exenatide across three levels of evidence:
In frataxin-deficient mice, exenatide improved glucose handling through enhanced insulin content and secretion. More importantly, it induced frataxin protein and iron-sulfur cluster-containing proteins in both pancreatic beta cells and brain tissue. It was also protective to sensory neurons in dorsal root ganglia, the neurons that die in Friedreich ataxia.
In patient-derived induced pluripotent stem cells (iPSCs) differentiated into beta cells and sensory neurons, GLP-1 analogs induced frataxin expression, reduced oxidative stress, and improved mitochondrial function.
In a pilot human trial, Friedreich ataxia patients treated with exenatide for 5 weeks showed modest frataxin induction in platelets. While modest, this is the first demonstration that a GLP-1 drug can increase frataxin in actual patients.
The mechanism involves GLP-1 receptor (incretin receptor) activation, identifying this receptor as a new therapeutic target for Friedreich ataxia.
Key Numbers
Frataxin induced in brain and beta cells; oxidative stress reduced in iPSC neurons; modest platelet frataxin increase in 5-week pilot; JCI Insight
How They Did This
Multi-level study: frataxin-deficient mouse models (in vivo), patient iPSC-derived beta cells and sensory neurons (in vitro), and a pilot clinical trial in Friedreich ataxia patients (5 weeks of exenatide treatment with platelet frataxin measurements). Published in JCI Insight.
Why This Research Matters
Friedreich ataxia has no treatment to slow disease progression. It affects about 1 in 50,000 people and causes progressive loss of coordination, heart disease, and diabetes. Finding that an already-approved drug (exenatide) can increase the deficient protein (frataxin) and improve the fundamental cellular defect (mitochondrial dysfunction) is a significant breakthrough that could lead to clinical trials.
The Bigger Picture
Friedreich ataxia has no disease-modifying treatment. Finding that an already-approved drug (exenatide) can boost the deficient protein across multiple evidence levels accelerates the path to clinical trials significantly compared to developing a new drug from scratch.
What This Study Doesn't Tell Us
The pilot trial was very small and short (5 weeks). Platelet frataxin is a surrogate marker that may not reflect brain frataxin levels. The frataxin induction in patients was described as "modest." Mouse models of Friedreich ataxia do not perfectly replicate human disease. Whether the frataxin increase is sufficient to slow neurodegeneration is unknown.
Questions This Raises
- ?Would longer exenatide treatment produce larger frataxin increases?
- ?Do platelet frataxin levels reliably reflect brain frataxin changes?
- ?Could higher GLP-1 drug doses achieve more clinically meaningful frataxin induction?
Trust & Context
- Key Stat:
- 3 evidence levels mouse, iPSC, and human pilot data all showing exenatide increases frataxin — the missing protein in Friedreich ataxia
- Evidence Grade:
- Moderate evidence. Consistent findings across mouse, cell, and human studies, though the pilot trial was very small and short with modest results.
- Study Age:
- Published in 2020 in JCI Insight. Larger clinical trials of GLP-1 drugs in Friedreich ataxia may be underway.
- Original Title:
- Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.
- Published In:
- JCI insight, 5(2) (2020)
- Authors:
- Igoillo-Esteve, Mariana, Oliveira, Ana F, Cosentino, Cristina, Fantuzzi, Federica, Demarez, Céline, Toivonen, Sanna, Hu, Amélie, Chintawar, Satyan, Lopes, Miguel, Pachera, Nathalie, Cai, Ying, Abdulkarim, Baroj, Rai, Myriam, Marselli, Lorella, Marchetti, Piero, Tariq, Mohammad, Jonas, Jean-Christophe, Boscolo, Marina, Pandolfo, Massimo, Eizirik, Décio L, Cnop, Miriam
- Database ID:
- RPEP-04871
Evidence Hierarchy
Frequently Asked Questions
What is Friedreich ataxia?
A genetic disease affecting about 1 in 50,000 people that causes progressive loss of coordination, heart problems, and diabetes. It is caused by insufficient production of frataxin, a mitochondrial protein. There is currently no treatment to slow the disease.
Could someone with Friedreich ataxia take exenatide now?
The pilot data is encouraging but very preliminary. Larger, longer clinical trials are needed to confirm benefit and establish appropriate dosing. Patients should discuss with their neurologist.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04871APA
Igoillo-Esteve, Mariana; Oliveira, Ana F; Cosentino, Cristina; Fantuzzi, Federica; Demarez, Céline; Toivonen, Sanna; Hu, Amélie; Chintawar, Satyan; Lopes, Miguel; Pachera, Nathalie; Cai, Ying; Abdulkarim, Baroj; Rai, Myriam; Marselli, Lorella; Marchetti, Piero; Tariq, Mohammad; Jonas, Jean-Christophe; Boscolo, Marina; Pandolfo, Massimo; Eizirik, Décio L; Cnop, Miriam. (2020). Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.. JCI insight, 5(2). https://doi.org/10.1172/jci.insight.134221
MLA
Igoillo-Esteve, Mariana, et al. "Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.." JCI insight, 2020. https://doi.org/10.1172/jci.insight.134221
RethinkPeptides
RethinkPeptides Research Database. "Exenatide induces frataxin expression and improves mitochond..." RPEP-04871. Retrieved from https://rethinkpeptides.com/research/igoillo-esteve-2020-exenatide-induces-frataxin-expression
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.